Hepatic impairment in coronavirus disease 2019 (COVID-19) may derive from cholangiocyte damage in the beginning, but not from direct infection of hepatocytes. Chronic liver disease patients co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited overexpression of angiotensin-converting enzyme 2 receptors and overwhelming cytokine storm. Consensus has been reached that we should encourage as many people as possible to be vaccinated in order to achieve herd immunity. SARS-CoV-2 vaccines can prevent or alleviate severe infection and cytokine storm. It is recommended that all adult patients with chronic liver diseases and liver transplant recipients should receive COVID-19 vaccines using the standard dose and schedule. Data is not yet sufficient to compare the efficacy of different types of vaccines used in chronic liver disease patients.
CITATION STYLE
Chen, L. P., Zeng, Q. H., Gong, Y. F., & Liang, F. L. (2021). Should people with chronic liver diseases be vaccinated against COVID-19? World Journal of Clinical Cases, 9(26), 7959–7962. https://doi.org/10.12998/wjcc.v9.i26.7959
Mendeley helps you to discover research relevant for your work.